Linvoseltamab During Maintenance Therapy
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
What will happen during the trial?
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will:
- Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) status. For participants that start the study with residual multiple myeloma cells in participants' bodies: to determine how long you remain MRD-.
- Increase the length of time that participants' disease is controlled. For participants with relapsed disease, to determine whether participants can re-attain MRD- status.
- Increase the length of time that participants' disease responds to treatment.
The researchers also want to find out the effects that linvoseltamab has on participants and participants' condition.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 32 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2084
- NCT Identifier
- NCT06910124
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.